The Mac1 ADP-ribosylhydrolase is a therapeutic target for SARS-CoV-2.

Saved in:
Bibliographic Details
Title: The Mac1 ADP-ribosylhydrolase is a therapeutic target for SARS-CoV-2.
Authors: Suryawanshi RK; Gladstone Institute of Virology, Gladstone Institutes, San Francisco, United States., Jaishankar P; Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, United States., Correy GJ; Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, United States., Rachman MM; Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, United States., O'Leary PC; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, United States., Taha TY; Gladstone Institute of Virology, Gladstone Institutes, San Francisco, United States.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, United States., Matsui Y; Gladstone Institute of Virology, Gladstone Institutes, San Francisco, United States., Zapatero-Belinchón FJ; Gladstone Institute of Virology, Gladstone Institutes, San Francisco, United States., McCavitt-Malvido M; Gladstone Institute of Virology, Gladstone Institutes, San Francisco, United States., Doruk YU; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, United States., Stevens MGV; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, United States., Diolaiti ME; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, United States., Jogalekar MP; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, United States., Chen H; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, United States., Richards AL; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, United States.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, United States.; Data Science and Biotechnology Institute, Gladstone Institutes, San Francisco, United States., Kongpracha P; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, United States.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, United States.; Data Science and Biotechnology Institute, Gladstone Institutes, San Francisco, United States., Bali S; Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, United States., Montano M; Gladstone Institute of Virology, Gladstone Institutes, San Francisco, United States., Rosecrans J; Gladstone Institute of Virology, Gladstone Institutes, San Francisco, United States., Matthay M; Data Science and Biotechnology Institute, Gladstone Institutes, San Francisco, United States., Togo T; Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, United States., Gonciarz RL; Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, United States., Gopalkrishnan S; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, United States., Neitz RJ; Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, United States.; Small Molecule Discovery Center, University of California San Francisco, San Francisco, United States., Krogan NJ; Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, United States.; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, United States.; Data Science and Biotechnology Institute, Gladstone Institutes, San Francisco, United States., Swaney DL; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, United States.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, United States.; Data Science and Biotechnology Institute, Gladstone Institutes, San Francisco, United States., Shoichet BK; Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, United States., Ott M; Gladstone Institute of Virology, Gladstone Institutes, San Francisco, United States.; Department of Medicine, University of California San Francisco, San Francisco, United States.; Chan Zuckerberg Biohub- San Francisco, San Francisco, San Francisco, United States., Renslo AR; Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, United States., Ashworth A; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, United States., Fraser JS; Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, United States.
Source: ELife [Elife] 2025 Nov 19; Vol. 14. Date of Electronic Publication: 2025 Nov 19.
Publication Type: Journal Article
Journal Info: Publisher: eLife Sciences Publications, Ltd Country of Publication: England NLM ID: 101579614 Publication Model: Electronic Cited Medium: Internet ISSN: 2050-084X (Electronic) Linking ISSN: 2050084X NLM ISO Abbreviation: Elife Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2050-084X
DOI:10.7554/eLife.103484